Checkmate Pharmaceuticals believes its approach to cancer treatment can make a certain type of immunotherapy work better, and it now has $27 million in additional funding to help build that case.
F-Prime Capital Partners, a new investor, led the Series B round of investment announced Thursday. Sofinnova Partners and venBio, who had invested in Cambridge, MA-based Checkmate’s Series A round two years ago, also invested in the latest round.
Checkmate’s lead drug, CMP-001, is an oligonucleotide, a type of drug that interrupts the cellular mechanisms involved in gene expression. The Checkmate drug is packaged within a virus-like particle, which is supposed... Read more »
UNDERWRITERS AND PARTNERS
